Sarepta Therapeutics’ (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern. …read more
Source:: Yahoo Finance
Sarepta Therapeutics’ (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern. …read more
Source:: Yahoo Finance
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.